{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T20:46:14Z","timestamp":1791751574567,"version":"4.3.4"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:00:00Z","timestamp":1791676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:00:00Z","timestamp":1791676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    3,4-Methylenedioxymethamphetamine (MDMA) has emerged as a potential treatment for post-traumatic stress disorder (PTSD). However, rapidly changing evidence in a fast-moving field can be challenging to integrate. Here, we present a living systematic review and open-data meta-analytic resource on MDMA treatment for PTSD. In this initial release, 6 randomized controlled trials comprising 286 participants are included in the database. All six studies included in the review to date are sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS). Our primary model uses inverse-variance random-effects meta-analysis of standardized mean differences on primary outcomes of PTSD. Compared to control conditions, MDMA-assisted therapy (MDMA-AT) showed a greater reduction in PTSD symptoms (Hedges\u2019\n                    <jats:italic>g<\/jats:italic>\n                    \u2009=\u2009\u22120.71). Meta-regressions on dosing variables were explored. Treatment with MDMA-AT as compared to placebo also resulted in higher response (risk ratio [\n                    <jats:italic>RR<\/jats:italic>\n                    ]\u2009=\u20091.35) and remission (\n                    <jats:italic>RR<\/jats:italic>\n                    \u2009=\u20092.25) rates. Most studies included in the database had a low risk of bias according to Cochrane guidelines, though these fail to capture pertinent challenges in the field such as expectancy, functional unblinding, potential issues with study conduct, and safety. The current findings were assigned an overall low certainty rating using the GRADE approach. Together, this systematic review and meta-analysis suggests that MDMA-AT results in short-term decreases in PTSD symptoms across studies to date. This living systematic review, meta-analysis, database, and online dashboard (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/sypres.io\" ext-link-type=\"uri\">sypres.io<\/jats:ext-link>\n                    ) will continue to be updated as evidence emerges, providing a valuable, open, and transparent resource for researchers in a rapidly evolving field.\n                  <\/jats:p>","DOI":"10.1038\/s41386-026-02575-z","type":"journal-article","created":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T07:35:25Z","timestamp":1791704125000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A living systematic review, meta-analysis, and open data resource of trials of MDMA-assisted therapy for PTSD"],"prefix":"10.1038","author":[{"given":"Brooke L.","family":"Sevchik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7102-7820","authenticated-orcid":false,"given":"S. Parker","family":"Singleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Analiese","family":"Lahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5497-2743","authenticated-orcid":false,"given":"Pim","family":"Cuijpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Harrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7999-7031","authenticated-orcid":false,"given":"Megan T.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6832-0639","authenticated-orcid":false,"given":"Sandeep M.","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8482-5461","authenticated-orcid":false,"given":"Eric C.","family":"Strain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7457-9073","authenticated-orcid":false,"given":"Simon N.","family":"Vandekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9604-6227","authenticated-orcid":false,"given":"David B.","family":"Yaden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Dworkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6538-9043","authenticated-orcid":false,"given":"J. Cobb","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7072-9399","authenticated-orcid":false,"given":"Theodore D.","family":"Satterthwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,11]]},"reference":[{"key":"2575_CR1","doi-asserted-by":"publisher","first-page":"2461435","DOI":"10.1080\/20008066.2025.2461435","volume":"16","author":"A Demesmaeker","year":"2025","unstructured":"Demesmaeker A, Creupelandt C, Leroy A, Vaiva G, D\u2019Hondt F. Impact of posttraumatic stress disorder and comorbid psychiatric conditions on suicide reattempts. Eur J Psychotraumatology. 2025;16:2461435.","journal-title":"Eur J Psychotraumatology"},{"key":"2575_CR2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.jad.2020.10.009","volume":"279","author":"V Fox","year":"2021","unstructured":"Fox V, Dalman C, Dal H, Hollander AC, Kirkbride JB, Pitman A. Suicide risk in people with post-traumatic stress disorder: a cohort study of 3.1 million people in Sweden. J Affect Disord. 2021;279:609\u2013616.","journal-title":"J Affect Disord"},{"key":"2575_CR3","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1001\/archgenpsychiatry.2008.557","volume":"66","author":"HC Wilcox","year":"2009","unstructured":"Wilcox HC, Storr CL, Breslau N. Posttraumatic stress disorder and suicide attempts in a community sample of urban American young adults. Arch Gen Psychiatry. 2009;66:305\u2013311.","journal-title":"Arch Gen Psychiatry"},{"key":"2575_CR4","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1176\/ps.62.3.pss6203_0272","volume":"62","author":"JN Doctor","year":"2011","unstructured":"Doctor JN, Zoellner LA, Feeny NC. Predictors of health-related quality-of-life utilities among persons with posttraumatic stress disorder. Psychiatr Serv. 2011;62:272\u2013277.","journal-title":"Psychiatr Serv"},{"key":"2575_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/traumacare4010008","volume":"4","author":"CR Miller","year":"2024","unstructured":"Miller CR, McDonald JE, Grau PP, Wetterneck CT. Quality of life in posttraumatic stress disorder: the role of posttraumatic anhedonia and depressive symptoms in a treatment-seeking community sample. Trauma Care. 2024;4:87\u201397.","journal-title":"Trauma Care"},{"key":"2575_CR6","doi-asserted-by":"publisher","first-page":"e1920476","DOI":"10.1001\/jamanetworkopen.2019.20476","volume":"3","author":"I Giesinger","year":"2020","unstructured":"Giesinger I, Li J, Takemoto E, Cone JE, Farfel MR, Brackbill RM. Association between posttraumatic stress disorder and mortality among responders and civilians following the September 11, 2001, disaster. JAMA Netw Open. 2020;3:e1920476.","journal-title":"JAMA Netw Open"},{"key":"2575_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-023-04716-w","volume":"23","author":"D Nilaweera","year":"2023","unstructured":"Nilaweera D, Phyo A, Teshale AB, Htun HL, Wrigglesworth J, Gurvich C, et al. Lifetime posttraumatic stress disorder as a predictor of mortality: a systematic review and meta-analysis. BMC Psychiatry. 2023;23:229.","journal-title":"BMC Psychiatry"},{"key":"2575_CR8","doi-asserted-by":"crossref","unstructured":"Davis LL, Schein J, Cloutier M, Gagnon-Sanschagrin P, Maitland J, Urganus A, et al. The economic burden of posttraumatic stress disorder in the United States from a societal perspective. J Clin Psychiatry. 2022;83:40672.","DOI":"10.4088\/JCP.21m14116"},{"key":"2575_CR9","doi-asserted-by":"publisher","first-page":"e0327778","DOI":"10.1371\/journal.pone.0327778","volume":"20","author":"F Stanicic","year":"2025","unstructured":"Stanicic F, Zah V, Grbic D, Vukicevic D, Angelo D, de. MDMA-assisted therapy and current treatment options for chronic, treatment-resistant, moderate or higher severity post-traumatic stress disorder: systematic literature review. PLOS ONE. 2025;20:e0327778.","journal-title":"PLOS ONE"},{"key":"2575_CR10","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1017\/S0033291717000708","volume":"47","author":"KC Koenen","year":"2017","unstructured":"Koenen KC, Ratanatharathorn A, Ng L, McLaughlin KA, Bromet EJ, Stein DJ, et al. Posttraumatic stress disorder in the World Mental Health Surveys. Psychol Med. 2017;47:2260\u20132274.","journal-title":"Psychol Med"},{"key":"2575_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa040603","volume":"351","author":"CW Hoge","year":"2004","unstructured":"Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI, Koffman RL. Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med. 2004;351:13\u201322.","journal-title":"N Engl J Med"},{"key":"2575_CR12","first-page":"2","volume":"3","author":"H Javidi","year":"2012","unstructured":"Javidi H, Yadollahie M. Post-traumatic stress disorder. Int J Occup Environ Med. 2012;3:2\u20139.","journal-title":"Int J Occup Environ Med"},{"key":"2575_CR13","doi-asserted-by":"publisher","unstructured":"VanElzakker MB, Staples-Bradley LK, Shin LM. The neurocircuitry of fear and PTSD. In: Vermetten E, Germain A, Neylan TC, editors. Sleep and combat-related post traumatic stress disorder. New York, NY: Springer;2018. p. 111\u2013125. https:\/\/doi.org\/10.1007\/978-1-4939-7148-0_10.","DOI":"10.1007\/978-1-4939-7148-0_10"},{"key":"2575_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1027\/0044-3409\/a000021","volume":"218","author":"A Ehlers","year":"2010","unstructured":"Ehlers A. Understanding and treating unwanted trauma memories in posttraumatic stress disorder. Z F\u00fcr Psychol J Psychol. 2010;218:141\u2013145.","journal-title":"Z F\u00fcr Psychol J Psychol"},{"key":"2575_CR15","doi-asserted-by":"crossref","unstructured":"Akiki TJ, Abdallah, CG. Are there effective psychopharmacologic treatments for PTSD? J Clin Psychiatry 2019;80:1309.","DOI":"10.4088\/JCP.18ac12473"},{"key":"2575_CR16","unstructured":"American Psychological Association. PTSD Treatments: APA\u2019s Clinical Practice Guideline recommends three interventions for treating posttraumatic stress disorder and suggests another four. 2025. apa.org. https:\/\/www.apa.org\/ptsd-guideline\/treatments."},{"key":"2575_CR17","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.cpr.2015.10.003","volume":"43","author":"K Cusack","year":"2016","unstructured":"Cusack K, Jonas DE, Forneris CA, Wines C, Sonis J, Middleton JC, et al. Psychological treatments for adults with posttraumatic stress disorder: a systematic review and meta-analysis. Clin Psychol Rev. 2016;43:128\u2013141.","journal-title":"Clin Psychol Rev"},{"key":"2575_CR18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1037\/pst0000231","volume":"56","author":"JL Hamblen","year":"2019","unstructured":"Hamblen JL, Norman SB, Sonis JH, Phelps AJ, Bisson JI, Nunes VD, et al. A guide to guidelines for the treatment of posttraumatic stress disorder in adults: an update. Psychotherapy. 2019;56:359\u2013373.","journal-title":"Psychotherapy"},{"key":"2575_CR19","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/acps.13366","volume":"145","author":"B Jericho","year":"2022","unstructured":"Jericho B, Luo A, Berle D. Trauma-focused psychotherapies for post-traumatic stress disorder: a systematic review and network meta-analysis. Acta Psychiatr Scand. 2022;145:132\u2013155.","journal-title":"Acta Psychiatr Scand"},{"key":"2575_CR20","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1017\/S0033291721001641","volume":"51","author":"N Morina","year":"2021","unstructured":"Morina N, Hoppen TH, Kip A. Study quality and efficacy of psychological interventions for posttraumatic stress disorder: a meta-analysis of randomized controlled trials. Psychol Med. 2021;51:1260\u20131270.","journal-title":"Psychol Med"},{"key":"2575_CR21","first-page":"546","volume":"118","author":"C Schrader","year":"2021","unstructured":"Schrader C, Ross A. A review of PTSD and current treatment strategies. Mol Med. 2021;118:546\u2013551.","journal-title":"Mol Med"},{"key":"2575_CR22","unstructured":"Shea MT. Present-centered therapy for PTSD. PTSD: National Center for PTSD. 2026. https:\/\/www.ptsd.va.gov\/professional\/treat\/txessentials\/present_centered_therapy.asp."},{"key":"2575_CR23","unstructured":"Mithoefer MC, Mithoefer A, Jerome L, Ruse J, Doblin R, Gibson E, et al. A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder. Version 8.1. Multidisciplinary Association for Psychedelic Studies (MAPS); 2017. Available from: https:\/\/maps.org\/wp-content\/uploads\/2022\/05\/MDMA-Assisted-Psychotherapy-Treatment-Manual-V8.1-22AUG2017.pdf."},{"key":"2575_CR24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/wps.21203","volume":"23","author":"P Cuijpers","year":"2024","unstructured":"Cuijpers P, Miguel C, Ciharova M, Harrer M, Basic D, Cristea IA, et al. Absolute and relative outcomes of psychotherapies for eight mental disorders: a systematic review and meta-analysis. World Psychiatry. 2024;23:267\u2013275.","journal-title":"World Psychiatry"},{"key":"2575_CR25","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1037\/a0031474","volume":"81","author":"ZE Imel","year":"2013","unstructured":"Imel ZE, Laska K, Jakupcak M, Simpson TL. Meta-analysis of dropout in treatments for posttraumatic stress disorder. J Consult Clin Psychol. 2013;81:394\u2013404.","journal-title":"J Consult Clin Psychol"},{"key":"2575_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.12703\/P7-43","volume":"7","author":"LM Najavits","year":"2015","unstructured":"Najavits LM. The problem of dropout from \u201cgold standard\u201d PTSD therapies. F1000Prime Rep. 2015;7:43.","journal-title":"F1000Prime Rep"},{"key":"2575_CR27","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1177\/0033294117727746","volume":"121","author":"BT Rutt","year":"2018","unstructured":"Rutt BT, Oehlert ME, Krieshok TS, Lichtenberg JW. Effectiveness of cognitive processing therapy and prolonged exposure in the Department of Veterans Affairs. Psychol Rep. 2018;121:282\u2013302.","journal-title":"Psychol Rep"},{"key":"2575_CR28","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/jts.22556","volume":"33","author":"NA Sciarrino","year":"2020","unstructured":"Sciarrino NA, Warnecke AJ, Teng EJ. A systematic review of intensive empirically supported treatments for posttraumatic stress disorder. J Trauma Stress. 2020;33:443\u2013454.","journal-title":"J Trauma Stress"},{"key":"2575_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.janxdis.2019.02.001","volume":"63","author":"RK Sripada","year":"2019","unstructured":"Sripada RK, Blow FC, Rauch S, Ganoczy D, Hoff R, Harpaz-Rotem I, et al. Examining the nonresponse phenomenon: factors associated with treatment response in a national sample of veterans undergoing residential PTSD treatment. J Anxiety Disord. 2019;63:18\u201325.","journal-title":"J Anxiety Disord"},{"key":"2575_CR30","first-page":"100093","volume":"4","author":"T Varker","year":"2021","unstructured":"Varker T, Jones KA, Arjmand HA, Hinton M, Hiles SA, Freijah I, et al. Dropout from guideline-recommended psychological treatments for posttraumatic stress disorder: a systematic review and meta-analysis. J Affect Disord Rep. 2021;4:100093.","journal-title":"J Affect Disord Rep"},{"key":"2575_CR31","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1001\/jama.2015.8370","volume":"314","author":"MM Steenkamp","year":"2015","unstructured":"Steenkamp MM, Litz BT, Hoge CW, Marmar CR. Psychotherapy for military-related PTSD: a review of randomized clinical trials. JAMA. 2015;314:489\u2013500.","journal-title":"JAMA"},{"key":"2575_CR32","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.biopsych.2017.11.023","volume":"84","author":"AA Feduccia","year":"2018","unstructured":"Feduccia AA, Mithoefer MC, Jerome L, Holland J, Emerson A, Doblin R. Response to the consensus statement of the PTSD Psychopharmacology Working Group. Biol Psychiatry. 2018;84:e21\u2013e22.","journal-title":"Biol Psychiatry"},{"key":"2575_CR33","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0269881110378371","volume":"25","author":"MC Mithoefer","year":"2011","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of \u00b13,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol (Oxf.). 2011;25:439\u2013452.","journal-title":"J Psychopharmacol (Oxf.)"},{"key":"2575_CR34","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.neuropharm.2017.10.003","volume":"128","author":"DW Curry","year":"2018","unstructured":"Curry DW, Young MB, Tran AN, Daoud GE, Howell LL. Separating the agony from ecstasy: R(-)-3,4-methylenedioxymethamphetamine has prosocial and therapeutic-like effects without signs of neurotoxicity in mice. Neuropharmacology. 2018;128:196\u2013206.","journal-title":"Neuropharmacology"},{"key":"2575_CR35","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1007\/s00213-017-4684-8","volume":"234","author":"MB Young","year":"2017","unstructured":"Young MB, Norrholm SD, Khoury LM, Jovanovic T, Rauch S, Reiff CM, et al. Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA). Psychopharmacology (Berl.). 2017;234:2883\u20132895.","journal-title":"Psychopharmacology (Berl.)"},{"key":"2575_CR36","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1017\/S1461145713001405","volume":"17","author":"RL Carhart-Harris","year":"2014","unstructured":"Carhart-Harris RL, Wall MB, Erritzoe D, Kaelen M, Ferguson B, De Meer I, et al. The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. Int J Neuropsychopharmacol. 2014;17:527\u2013540.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2575_CR37","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/npp.2017.171","volume":"43","author":"MK Doss","year":"2018","unstructured":"Doss MK, Weafer J, Gallo DA, de Wit H. MDMA impairs both the encoding and retrieval of emotional recollections. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2018;43:791\u2013800.","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"2575_CR38","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1177\/02698811211069124","volume":"36","author":"JL Maples-Keller","year":"2022","unstructured":"Maples-Keller JL, Norrholm SD, Burton M, Reiff C, Coghlan C, Jovanovic T, et al. A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults. J Psychopharmacol (Oxf.). 2022;36:368\u2013377.","journal-title":"J Psychopharmacol (Oxf.)"},{"key":"2575_CR39","doi-asserted-by":"publisher","first-page":"906639","DOI":"10.3389\/fphar.2022.906639","volume":"13","author":"P Vizeli","year":"2022","unstructured":"Vizeli P, Straumann I, Duthaler U, Varghese N, Eckert A, Paulus MP, et al. Effects of 3,4-methylenedioxymethamphetamine on conditioned fear extinction and retention in a crossover study in healthy subjects. Front Pharmacol. 2022;13:906639.","journal-title":"Front Pharmacol"},{"key":"2575_CR40","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.physbeh.2018.12.007","volume":"199","author":"HS Hake","year":"2019","unstructured":"Hake HS, Davis J, Wood RR, Tanner MK, Loetz EC, Sanchez A, et al. 3,4-methylenedioxymethamphetamine (MDMA) impairs the extinction and reconsolidation of fear memory in rats. Physiol Behav. 2019;199:343\u2013350.","journal-title":"Physiol Behav"},{"key":"2575_CR41","doi-asserted-by":"publisher","first-page":"947622","DOI":"10.3389\/fpsyt.2022.947622","volume":"13","author":"SP Singleton","year":"2023","unstructured":"Singleton SP, Wang JB, Mithoefer M, Hanlon C, George MS, Mithoefer A, et al. Altered brain activity and functional connectivity after MDMA-assisted therapy for post-traumatic stress disorder. Front Psychiatry. 2023;13:947622.","journal-title":"Front Psychiatry"},{"key":"2575_CR42","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.pnpbp.2018.03.003","volume":"84","author":"AA Feduccia","year":"2018","unstructured":"Feduccia AA, Mithoefer MC. MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms? Prog Neuropsychopharmacol Biol Psychiatry. 2018;84:221\u2013228.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2575_CR43","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1176\/appi.focus.20220088","volume":"21","author":"BR Lewis","year":"2023","unstructured":"Lewis BR, Byrne K. A review of MDMA-assisted therapy for posttraumatic stress disorder. Focus. 2023;21:247\u2013256.","journal-title":"Focus"},{"key":"2575_CR44","doi-asserted-by":"publisher","unstructured":"Reardon S. MDMA therapy for PTSD rejected by FDA panel. Nature. 2024. https:\/\/doi.org\/10.1038\/d41586-024-01622-3.","DOI":"10.1038\/d41586-024-01622-3"},{"key":"2575_CR45","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27:1025\u20131033.","journal-title":"Nat Med"},{"key":"2575_CR46","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","volume":"29","author":"JM Mitchell","year":"2023","unstructured":"Mitchell JM, Ot'alora G M, van der Kolk B, Shannon S, Bogenschutz M, Gelfand Y, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023;29:2473\u20132480.","journal-title":"Nat Med"},{"key":"2575_CR47","doi-asserted-by":"publisher","first-page":"100008","DOI":"10.1016\/j.psyche.2026.100008","volume":"3","author":"R Yehuda","year":"2026","unstructured":"Yehuda R, Lehrner A, Sperka M, Glatman Zaretsky T, Pratchett LC, Haznedar MM, et al. The case for an integrative model: hypotheses and rationale for integrative MDMA-Assisted Psychotherapy (IMAP). Psychedelics. 2026;3:100008.","journal-title":"Psychedelics"},{"key":"2575_CR48","unstructured":"Department of Veterans Affairs, Department of Defense. VA\/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder. Version 4.0. Washington, DC: Management of Posttraumatic Stress Disorder and Acute Stress Disorder Work Group; 2023. Available from: https:\/\/www.healthquality.va.gov\/guidelines\/MH\/ptsd\/."},{"key":"2575_CR49","unstructured":"Multidisciplinary Association for Psychedelic Studies. A test of MDMA-assisted psychotherapy in subjects with chronic posttraumatic stress disorder (PTSD): subject information and consent form [Informed consent form]."},{"key":"2575_CR50","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1176\/appi.ajp.20230661","volume":"181","author":"KC O'donnell","year":"2024","unstructured":"O'donnell KC, Anderson BT, Barrett FS, Bogenschutz MP, Grob CS, Hendricks PS, et al. Misinterpretations and omissions: a critical response to goodwin and colleagues\u2019 commentary on psilocybin-assisted therapy. Am J Psychiatry. 2024;181:74\u201375.","journal-title":"Am J Psychiatry"},{"key":"2575_CR51","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/jamapsychiatry.2024.2887","volume":"81","author":"IA Cristea","year":"2024","unstructured":"Cristea IA, Cuijpers P, Halvorsen J\u00d8. The psychotherapy in MDMA-assisted psychotherapy. JAMA Psychiatry. 2024;81:1053\u20131054.","journal-title":"JAMA Psychiatry"},{"key":"2575_CR52","doi-asserted-by":"publisher","first-page":"204512532311984","DOI":"10.1177\/20451253231198466","volume":"13","author":"M van Elk","year":"2023","unstructured":"van Elk M, Fried EI. History repeating: guidelines to address common problems in psychedelic science. Ther Adv Psychopharmacol. 2023;13:20451253231198466.","journal-title":"Ther Adv Psychopharmacol"},{"key":"2575_CR53","doi-asserted-by":"publisher","first-page":"109735","DOI":"10.1016\/j.pnpbp.2019.109735","volume":"96","author":"A Bahji","year":"2020","unstructured":"Bahji A, Forsyth A, Groll D, Hawken ER. Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: a systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2020;96:109735.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2575_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02791072.2023.2278586","volume":"57","author":"A Bahji","year":"2025","unstructured":"Bahji A, Lunsky I, Gutierrez G, Vazquez G. Efficacy and safety of four psychedelic-assisted therapies for adults with symptoms of depression, anxiety, and posttraumatic stress disorder: a systematic review and meta-analysis. J Psychoactive Drugs. 2025;57:1\u201316.","journal-title":"J Psychoactive Drugs"},{"key":"2575_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02791072.2025.2577308","volume":"0","author":"B Brett","year":"2025","unstructured":"Brett B, Bynum C. MDMA-assisted psychotherapy for PTSD: a systematic review of randomized control trials. J Psychoactive Drugs. 2025;0:1\u201313.","journal-title":"J Psychoactive Drugs"},{"key":"2575_CR56","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.euroneuro.2025.09.011","volume":"101","author":"M H\u00f8jlund","year":"2025","unstructured":"H\u00f8jlund M, Kafali HY, K\u0131rm\u0131z\u0131 B, Fusar-Poli P, Correll CU, Cortese S, et al. Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: a living systematic review with meta-analysis. Eur. Neuropsychopharmacol. 2025;101:41\u201355.","journal-title":"Eur. Neuropsychopharmacol"},{"key":"2575_CR57","first-page":"274","volume":"8","author":"AP Hood","year":"2024","unstructured":"Hood AP, Corlett CE, Alldredge CT, Elkins GR. Critical review of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder: unanswered questions and future directions. J Psychedelic Stud. 2024;8:274\u2013285.","journal-title":"J Psychedelic Stud"},{"key":"2575_CR58","doi-asserted-by":"publisher","DOI":"10.1080\/20008198.2020.1853379","volume":"12","author":"MD Hoskins","year":"2021","unstructured":"Hoskins MD, Sinnerton R, Nakamura A, Underwood JFG, Slater A, Lewis C, et al. Pharmacological-assisted psychotherapy for post traumatic stress disorder: a systematic review and meta-analysis. Eur J Psychotraumatology. 2021;12:1853379.","journal-title":"Eur J Psychotraumatology"},{"key":"2575_CR59","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1177\/0269881120965915","volume":"35","author":"BJ Illingworth","year":"2021","unstructured":"Illingworth BJ, Lewis DJ, Lambarth AT, Stocking K, Duffy JM, Jelen LA, et al. A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: a systematic review and meta-analysis. J Psychopharmacol (Oxf). 2021;35:501\u2013511.","journal-title":"J Psychopharmacol (Oxf)"},{"key":"2575_CR60","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1177\/00048674221083868","volume":"57","author":"S Kisely","year":"2023","unstructured":"Kisely S, Connor M, Somogyi AA, Siskind D. A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders. Aust N Z J Psychiatry. 2023;57:362\u2013378.","journal-title":"Aust N Z J Psychiatry"},{"key":"2575_CR61","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/npr2.12485","volume":"44","author":"G Shahrour","year":"2024","unstructured":"Shahrour G, Sohail K, Elrais S, Khan MH, Javeid J, Samdani K, et al. MDMA-assisted psychotherapy for the treatment of PTSD: a systematic review and meta-analysis of randomized controlled trials (RCTs). Neuropsychopharmacol Rep. 2024;44:672\u2013681.","journal-title":"Neuropsychopharmacol Rep"},{"key":"2575_CR62","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/jcph.1995","volume":"62","author":"KW Smith","year":"2022","unstructured":"Smith KW, Sicignano DJ, Hernandez AV, White CM. MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: a systematic review with meta-analysis. J Clin Pharmacol. 2022;62:463\u2013471.","journal-title":"J Clin Pharmacol"},{"key":"2575_CR63","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/00048674251315642","volume":"59","author":"S A Bratuskins","year":"2025","unstructured":"A Bratuskins S, Sultani MS, Blakeley B, Davey CG, Bell JS. Safety and efficacy of methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in post-traumatic stress disorder: an overview of systematic reviews and meta-analyses. Aust N Z J Psychiatry. 2025;59:339\u2013360.","journal-title":"Aust N Z J Psychiatry"},{"key":"2575_CR64","doi-asserted-by":"publisher","first-page":"116043","DOI":"10.1016\/j.psychres.2024.116043","volume":"339","author":"J Yang","year":"2024","unstructured":"Yang J, Wang N, Luo W, Gao J. The efficacy and safety of MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: a systematic review and meta-analysis from randomized controlled trials. Psychiatry Res. 2024;339:116043.","journal-title":"Psychiatry Res"},{"key":"2575_CR65","doi-asserted-by":"crossref","unstructured":"\u017duljevi\u0107 MF, Vidak M, Vukojevi\u0107 J, Hren D, Pericic TP. 3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder (PTSD) in adults\u2014\u017duljevi\u0107, MF\u20142022 | Cochrane Library. https:\/\/www-cochranelibrary-com.proxy.library.upenn.edu\/cdsr\/doi\/10.1002\/14651858.CD015345\/full.","DOI":"10.1002\/14651858.CD015345"},{"key":"2575_CR66","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41562-026-02428-1","volume":"10","author":"IA Iversen","year":"2026","unstructured":"Iversen IA, Quintana DS. The value of living systematic reviews. Nat Hum Behav. 2026;10:647\u2013649. https:\/\/doi.org\/10.1038\/s41562-026-02428-1.","journal-title":"Nat Hum Behav"},{"key":"2575_CR67","unstructured":"Search ClinicalTrials.gov for: Other terms: AREA[InterventionSearch](MDMA OR methylenedioxymethamphetamine OR midomafetamine) NOT AREA[InterventionSearch](cannabis OR dronabinol OR cannabinoid) AND AREA[OverallStatus](RECRUITING OR ACTIVE_NOT_RECRUITING OR NOT_YET_RECRUITING) AND AREA[Phase](PHASE3 OR PHASE2) AND AREA[Condition](PTSD OR post traumatic stress) | Card Expert Search | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/expert-search."},{"key":"2575_CR68","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/978-1-0716-1566-9_7","volume":"2345","author":"M Simmonds","year":"2022","unstructured":"Simmonds M, Elliott JH, Synnot A, Turner T. Living systematic reviews. Methods Mol Biol. 2022;2345:121\u2013134.","journal-title":"Methods Mol Biol"},{"key":"2575_CR69","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u2013926.","journal-title":"BMJ"},{"key":"2575_CR70","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence\u2014imprecision. J Clin Epidemiol. 2011;64:1283\u20131293.","journal-title":"J Clin Epidemiol"},{"key":"2575_CR71","doi-asserted-by":"publisher","first-page":"2136921","DOI":"10.1001\/jamanetworkopen.2021.36921","volume":"5","author":"PP Schnurr","year":"2022","unstructured":"Schnurr PP, Chard KM, Ruzek JI, Chow BK, Resick PA, Foa EB, et al. Comparison of prolonged exposure vs cognitive processing therapy for treatment of posttraumatic stress disorder among US veterans: a randomized clinical trial. JAMA Netw Open. 2022;5:2136921.","journal-title":"JAMA Netw Open"},{"key":"2575_CR72","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3102\/10769986030003261","volume":"30","author":"W Viechtbauer","year":"2005","unstructured":"Viechtbauer W. Bias and efficiency of meta-analytic variance estimators in the random-effects model. J Educ Behav Stat. 2005;30:261\u2013293.","journal-title":"J Educ Behav Stat"},{"key":"2575_CR73","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/sim.2514","volume":"26","author":"W Viechtbauer","year":"2007","unstructured":"Viechtbauer W. Confidence intervals for the amount of heterogeneity in meta-analysis. Stat Med. 2007;26:37\u201352.","journal-title":"Stat Med"},{"key":"2575_CR74","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1002\/sim.1482","volume":"22","author":"G Knapp","year":"2003","unstructured":"Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. Stat Med. 2003;22:2693\u20132710.","journal-title":"Stat Med"},{"key":"2575_CR75","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u2013634.","journal-title":"BMJ"},{"key":"2575_CR76","doi-asserted-by":"publisher","first-page":"377","DOI":"10.6028\/jres.087.022","volume":"87","author":"RC Paule","year":"1982","unstructured":"Paule RC, Mandel J. Consensus values and weighting factors. J Res Natl Bur Stand. 1982;87:377\u2013385.","journal-title":"J Res Natl Bur Stand"},{"key":"2575_CR77","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s11121-021-01246-3","volume":"23","author":"JE Pustejovsky","year":"2022","unstructured":"Pustejovsky JE, Tipton E. Meta-analysis with robust variance estimation: expanding the range of working models. Prev Sci. 2022;23:425\u2013438.","journal-title":"Prev Sci"},{"key":"2575_CR78","doi-asserted-by":"publisher","unstructured":"Williams DR, Rast P, B\u00fcrkner P-C. Bayesian meta-analysis with weakly informative prior distributions. 2018. Preprint at https:\/\/doi.org\/10.31234\/osf.io\/7tbrm.","DOI":"10.31234\/osf.io\/7tbrm"},{"key":"2575_CR79","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/jrsm.1475","volume":"12","author":"C R\u00f6ver","year":"2021","unstructured":"R\u00f6ver C, Bender R, Dias S, Schmid CH, Schmidli H, Sturtz S, et al. On weakly informative prior distributions for the heterogeneity parameter in Bayesian random-effects meta-analysis. Res Synth Methods. 2021;12:448\u2013474.","journal-title":"Res Synth Methods"},{"key":"2575_CR80","doi-asserted-by":"publisher","unstructured":"Harrer M, Kuper P, Sprenger A, Cuijpers P. metapsyTools: several R helper functions for the Metapsy Database. R package. 2022. https:\/\/doi.org\/10.5281\/zenodo.6566632. Available from: https:\/\/tools.metapsy.org.","DOI":"10.5281\/zenodo.6566632"},{"key":"2575_CR81","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153\u2013160.","journal-title":"Evid Based Ment Health"},{"key":"2575_CR82","doi-asserted-by":"crossref","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor Package. J Stat Softw 2010;36:1\u201348.","DOI":"10.18637\/jss.v036.i03"},{"key":"2575_CR83","unstructured":"Harrer M, Cuijpers P, Furukawa T, Ebert DD. Dmetar: companion R package for the guide \u2018Doing Meta-Analysis in R\u2019. 2019."},{"key":"2575_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v093.i06","volume":"93","author":"C R\u00f6ver","year":"2020","unstructured":"R\u00f6ver C. Bayesian random-effects meta-analysis using the bayesmeta R package. J Stat Softw. 2020;93:1\u201351.","journal-title":"J Stat Softw"},{"key":"2575_CR85","doi-asserted-by":"publisher","unstructured":"Singleton P, Sevchik B, Harrer M. metapsy-project\/data-ptsd-mdmactr: Version 26.0.1. Zenodo. 2026. https:\/\/doi.org\/10.5281\/zenodo.19233985.","DOI":"10.5281\/zenodo.19233985"},{"key":"2575_CR86","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","volume":"5","author":"MC Mithoefer","year":"2018","unstructured":"Mithoefer MC, Mithoefer AT, Feduccia AA, Jerome L, Wagner M, Wymer J, et al. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry. 2018;5:486\u2013497.","journal-title":"Lancet Psychiatry"},{"key":"2575_CR87","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1177\/0269881118806297","volume":"32","author":"MJ Ot\u2019alora G","year":"2018","unstructured":"Ot\u2019alora G MJ, Poulter B, Van Derveer JW, Giron SG, Jerome L, et al. 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: a randomized phase 2 controlled trial. J Psychopharmacol (Oxf.). 2018;32:1295\u20131307.","journal-title":"J Psychopharmacol (Oxf.)"},{"key":"2575_CR88","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/0269881112464827","volume":"27","author":"P Oehen","year":"2013","unstructured":"Oehen P, Traber R, Widmer V, Schnyder U. A randomized, controlled pilot study of MDMA (\u00b13,4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD). J Psychopharmacol (Oxf.). 2013;27:40\u201352.","journal-title":"J Psychopharmacol (Oxf.)"},{"key":"2575_CR89","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40501-025-00369-6","volume":"12","author":"MF \u017duljevi\u0107","year":"2025","unstructured":"\u017duljevi\u0107 MF, Vi\u0111ak M, Vukojevi\u0107 J, Hren D, Peri\u010di\u0107 TP. MDMA-assisted psychotherapy for PTSD: evidence synthesis and methodological challenges in a rapidly evolving field. Curr Treat Options Psychiatry. 2025;12:33.","journal-title":"Curr Treat Options Psychiatry"},{"key":"2575_CR90","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/02791072.2014.877321","volume":"46","author":"A Emerson","year":"2014","unstructured":"Emerson A, Pont\u00e9 L, Jerome L, Doblin R. History and future of the Multidisciplinary Association for Psychedelic Studies (MAPS). J Psychoactive Drugs. 2014;46:27\u201336.","journal-title":"J Psychoactive Drugs"},{"key":"2575_CR91","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1177\/00048674221127186","volume":"57","author":"G Bedi","year":"2023","unstructured":"Bedi G, Cotton SM, Guerin AA, Jackson HJ. MDMA-assisted psychotherapy for post-traumatic stress disorder: the devil is in the detail. Aust N Z J Psychiatry. 2023;57:476\u2013481.","journal-title":"Aust N Z J Psychiatry"},{"key":"2575_CR92","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1038\/s41591-021-01525-0","volume":"27","author":"J\u00d8 Halvorsen","year":"2021","unstructured":"Halvorsen J\u00d8, Naudet F, Cristea IA. Challenges with benchmarking of MDMA-assisted psychotherapy. Nat Med. 2021;27:1689\u20131690.","journal-title":"Nat Med"},{"key":"2575_CR93","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.euroneuro.2023.09.007","volume":"78","author":"RJ Zeifman","year":"2024","unstructured":"Zeifman RJ, Maia LO. Methodological concerns in psychedelic research: the issues of nonequivalent psychological support and generalizability. Eur Neuropsychopharmacol. 2024;78:13\u201315.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2575_CR94","doi-asserted-by":"publisher","first-page":"873279","DOI":"10.3389\/fpsyg.2022.873279","volume":"13","author":"DB Yaden","year":"2022","unstructured":"Yaden DB, Earp D, Graziosi M, Friedman-Wheeler D, Luoma JB, Johnson MW. Psychedelics and psychotherapy: cognitive-behavioral approaches as default. Front Psychol. 2022;13:873279.","journal-title":"Front Psychol"},{"key":"2575_CR95","first-page":"512","volume":"9","author":"B Szigeti","year":"2024","unstructured":"Szigeti B, Heifets BD. Expectancy effects in psychedelic trials. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024;9:512\u2013521.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"2575_CR96","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1080\/17512433.2021.1951473","volume":"14","author":"EE Schenberg","year":"2021","unstructured":"Schenberg EE. Who is blind in psychedelic research? Letter to the editor regarding: blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol. 2021;14:1317\u20131319.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2575_CR97","doi-asserted-by":"publisher","DOI":"10.31234\/osf.io\/caup9_v1","author":"S Muthukumaraswamy","year":"2025","unstructured":"Muthukumaraswamy S, Baggott M, Schenberg EE, Repantis D, Wolff M, Forsyth A, et al. Psychedelic assisted therapy as a complex intervention: implications for clinical trial design. Ther Adv Psychopharmacol. 2025. https:\/\/doi.org\/10.31234\/osf.io\/caup9_v1.","journal-title":"Ther Adv Psychopharmacol"},{"key":"2575_CR98","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1007\/s00213-022-06221-6","volume":"239","author":"M Butler","year":"2022","unstructured":"Butler M, Jelen L, Rucker J. Expectancy in placebo-controlled trials of psychedelics: if so, so what? Psychopharmacology (Berl.). 2022;239:3047\u20133055.","journal-title":"Psychopharmacology (Berl.)"},{"key":"2575_CR99","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Complete response letter for NDA 215455 [Letter to Lykos Therapeutics]. 2024."},{"key":"2575_CR100","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41386-024-01865-8","volume":"49","author":"J Colcott","year":"2024","unstructured":"Colcott J, Guerin AA, Carter O, Meikle S, Bedi G. Side-effects of mdma-assisted psychotherapy: a systematic review and meta-analysis. Neuropsychopharmacology. 2024;49:1208\u20131226.","journal-title":"Neuropsychopharmacology"},{"key":"2575_CR101","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s44220-024-00373-4","volume":"3","author":"SP Singleton","year":"2025","unstructured":"Singleton SP, Sevchik BL, Vandekar SN, Strain EC, Nayak SM, Dworkin RH, et al. An initiative for living evidence synthesis in clinical psychedelic research. Nat Ment Health. 2025;3:3\u20135.","journal-title":"Nat Ment Health"},{"key":"2575_CR102","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209\u20131223.","journal-title":"N Engl J Med"},{"key":"2575_CR103","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/archpsyc.64.4.419","volume":"64","author":"DJ Miklowitz","year":"2007","unstructured":"Miklowitz DJ, Otto MW, Frank E, Reilly-Harrington NA, Wisniewski SR, Kogan JN, et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry. 2007;64:419\u2013426.","journal-title":"Arch Gen Psychiatry"},{"key":"2575_CR104","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/070674371005500304","volume":"55","author":"SV Parikh","year":"2010","unstructured":"Parikh SV, LeBlanc SR, Ovanessian MM. Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Can J Psychiatry Rev Can Psychiatr. 2010;55:136\u2013143.","journal-title":"Can J Psychiatry Rev Can Psychiatr"},{"key":"2575_CR105","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","volume":"163","author":"TS Stroup","year":"2006","unstructured":"Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163:611\u2013622.","journal-title":"Am J Psychiatry"},{"key":"2575_CR106","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","volume":"163","author":"MH Trivedi","year":"2006","unstructured":"Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28\u201340.","journal-title":"Am J Psychiatry"},{"key":"2575_CR107","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11920-007-0061-3","volume":"9","author":"D Warden","year":"2007","unstructured":"Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9:449\u2013459.","journal-title":"Curr Psychiatry Rep"},{"key":"2575_CR108","unstructured":"Multidisciplinary association for psychedelic studies. statement: public announcement of ethical violation by former MAPS-Sponsored Investigators. 2022. https:\/\/maps.org\/2019\/05\/24\/statement-public-announcement-of-ethical-violation-by-former-maps-sponsored-investigators\/."}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02575-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02575-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02575-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T20:02:06Z","timestamp":1791748926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02575-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,11]]},"references-count":108,"alternative-id":["2575"],"URL":"https:\/\/doi.org\/10.1038\/s41386-026-02575-z","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,11]]},"assertion":[{"value":"22 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Over the last three years, ECS has had grant funding to his institution from NIH; editing payments from Wolters\u2013Kluwer; compensation for serving on boards or consulting from Eli Lilly and Company, Boehringer Ingelheim, and Dimerx; medical devices supplied to his institution for his research: Masimo; and he has conducted medical-legal consultations. He also has served on the board of directors (unpaid) for a treatment program: Ashley Addiction Treatment. SMN is a co-investigator on a Usona Institute-sponsored trial of psilocybin for Major Depressive Disorder. DBY has received research support from the NIH, the Gracias Family Foundation, the Heffter Research Institute, and philanthropic donors to the Johns Hopkins Center for Psychedelic and Consciousness Research. He co-directs the Hub at Oxford for Psychedelic Ethics (HOPE), which has received a small anonymous donation to support travel for underrepresented workshop participants; DBY does not personally receive financial support for this role. DBY has received a consulting fee from Soneira and educational speaking fees from the Integrative Psychiatry Institute. RHD, since January 1, 2023, has received research grants and contracts from the US Food and Drug Administration and the US National Institutes of Health and compensation for serving on advisory boards or consulting on clinical trial methods from Abbvie, Aditum, Akigai, Allay, AM-Pharma, Biogen, Biohaven, Biomedical Statistical Consulting, Bsense, Centrexion, Cyllene, Coalition for Aligning Sciences, Collegium, Contineum, Cool Flame, Definium (formerly Mind Medicine; also equity), Eccogene, Eli Lilly, Emmes, Epizon, Ethismos (equity), Eurofarma, GlaxoSmithKline, JCARE, JucaBio, Kriya, Latigo, Mainstay, Maxona, Merck, Merz, Nocicera, Noema, Orion, Regenacy, Rho, Salvia, Sangamo, Semnur, SIMR Biotech, SiteOne, Sparian, SPM Therapeutics, Tiefenbacher, Validae, Ventus, Vertanical, Vertex, Viscera, and Xenon. All other authors have no conflicts to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}